[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
78 previously untreated patients with acute non-lymphoblastic leukemia (ANLL) were assigned to cytosar-anthracyclines therapeutic programs: 29 (group I) received daunorubicin and AraC, 18 (group II) aclacinomycin A and AraC, 12 (group III) the scheme 3 + 7 with 12 mg/m2 novantron instead of daunorubicin, 19 (group IV) the scheme 3 + 7 with 12 mg/m2 idarubicin and cytosar. Groups I-III comprised both prognostically favorable and unfavorable ANLL variants, group 4 patients had for the most part unfavorable prognosis (MO-M3). A mean age of the patients was 41-42. Complete remissions were observed in 17 (58.6%), 9 (50%), 10 (83.3%), 11 (57.9%) patients of groups I, II, III and IV, respectively. An initial course of the treatment produced complete remissions in 65%, 33%, 80% and 90.9% of them, respectively. A mean duration of cytostatic leukothrombocytopenia was the longest in groups III and IV (16-22 days). Nonhematological toxicity occurred in the form of enteropathy and hepatitis. During the remission induction and consolidation 76% of the deaths were caused by infection and hemorrhagic diathesis. The median remission lasted 17.5, 13.5 and 5 months in groups I, II and III, respectively, and was not reached in group IV because of continuing remission in 50% of the patients by the end of the follow-up period (14 months). A 2-year survival rate was observed in 25% (group I), 11% (group II), 30% (group III) and 40% (group IV).
Volkova
M A
MA
Kaletin
G I
GI
Pirogova
N A
NA
D015250:Aclarubicin / Q000008:administration & dosage; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008942:Mitoxantrone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D015250:Aclarubicin; D004317:Doxorubicin; D011239:Prednisolone; D008942:Mitoxantrone; D015255:Idarubicin; D003630:Daunorubicin
Sravnitel'naia otsenka éffektivnosti razlichnykh skhem terapii ostrykh nelimfoblastnykh leĭkozov.